There has been one publication on ERAP1 at the ACR 2015 Annual Meeting in San Francisco. ERAP1 (endoplasmic reticulum aminopeptidase 1) has a strong genetic association of with ankylosing spondylitis, which is restricted to HLA-B27 positive cases. I’ve become interested while being at the 2014 EULAR Meeting in Paris. And now we have a new tiny piece of evidence that there might be a drug in the far future.
Tri M. Tran and colleagues presented: “ERAP1 Deficiency Protects HLA-B27 Transgenic Rats from Arthritis”. Conclusion: “Complete absence of ERAP1 protected B27-TG rats from arthritis, but led to an increase in gut inflammation, suggesting different effects on pathogenic mechanisms involved in arthritis and colitis. B27-TG rats heterologous for ERAP1 exhibited higher incidence of arthritis concomitant with lower inflammation in the gut as compared to ERAP1-/- .This novel model provides an opportunity to better understand the mechanism(s) by which HLA-B27 contributes to SpA pathogenesis”.
Protection from arthritis, but increase in gut inflammation. What goes through my mind now? Far future, individually tailored therapy, basic science … Yes, and far too early to speculate on a new drug.
Tran TM, Hong S, Gill T, Bennett J, Sikora K, Colbert RA. ERAP1 Deficiency Protects HLA-B27 Transgenic Rats from Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). http://acrabstracts.org/abstract/erap1-deficiency-protects-hla-b27-transgenic-rats-from-arthritis/. Accessed November 20, 2015.
ERAP1 at the EULAR 2014 Meeting in Paris http://rheumatologe.blogspot.de/2014/07/erap1-at-eular-2014-meeting-in-paris.html